Indicazioni terapeutiche approvate e ulteriori possibili applicazioni dei farmaci biologici anti-TNFα

Translated title of the contribution: Approved indications and other possible utilizations of anti-TNFα biologic drugs

Walter Grassi, C. Montecucco

Research output: Contribution to journalArticle

Abstract

The article describes the EMEA approved indications of TNFα antagonists (adalimumab, etanercept and infliximab) in the various clinical conditions and their increasing use in diseases other than those already approved. The Authors discuss their use during pregnancy, the efficacy of a second TNFα antagonist after failure or side effects development with a previous biologic agent and the different efficacy of the various agents depending on the different clinical conditions.

Original languageItalian
Pages (from-to)30-33
Number of pages4
JournalReumatismo
Volume57
Issue numberSUPPL. 4
Publication statusPublished - 2005

Fingerprint

Biological Factors
Pregnancy
Pharmaceutical Preparations
Etanercept
Adalimumab
Infliximab

ASJC Scopus subject areas

  • Rheumatology

Cite this

Indicazioni terapeutiche approvate e ulteriori possibili applicazioni dei farmaci biologici anti-TNFα. / Grassi, Walter; Montecucco, C.

In: Reumatismo, Vol. 57, No. SUPPL. 4, 2005, p. 30-33.

Research output: Contribution to journalArticle

@article{aa7c9f0bf39848a89d7645361003509c,
title = "Indicazioni terapeutiche approvate e ulteriori possibili applicazioni dei farmaci biologici anti-TNFα",
abstract = "The article describes the EMEA approved indications of TNFα antagonists (adalimumab, etanercept and infliximab) in the various clinical conditions and their increasing use in diseases other than those already approved. The Authors discuss their use during pregnancy, the efficacy of a second TNFα antagonist after failure or side effects development with a previous biologic agent and the different efficacy of the various agents depending on the different clinical conditions.",
keywords = "Drugs, Rheumatic diseases, Tumor Necrosis Factor α",
author = "Walter Grassi and C. Montecucco",
year = "2005",
language = "Italian",
volume = "57",
pages = "30--33",
journal = "Reumatismo",
issn = "0048-7449",
publisher = "PAGEPRESS PUBL",
number = "SUPPL. 4",

}

TY - JOUR

T1 - Indicazioni terapeutiche approvate e ulteriori possibili applicazioni dei farmaci biologici anti-TNFα

AU - Grassi, Walter

AU - Montecucco, C.

PY - 2005

Y1 - 2005

N2 - The article describes the EMEA approved indications of TNFα antagonists (adalimumab, etanercept and infliximab) in the various clinical conditions and their increasing use in diseases other than those already approved. The Authors discuss their use during pregnancy, the efficacy of a second TNFα antagonist after failure or side effects development with a previous biologic agent and the different efficacy of the various agents depending on the different clinical conditions.

AB - The article describes the EMEA approved indications of TNFα antagonists (adalimumab, etanercept and infliximab) in the various clinical conditions and their increasing use in diseases other than those already approved. The Authors discuss their use during pregnancy, the efficacy of a second TNFα antagonist after failure or side effects development with a previous biologic agent and the different efficacy of the various agents depending on the different clinical conditions.

KW - Drugs

KW - Rheumatic diseases

KW - Tumor Necrosis Factor α

UR - http://www.scopus.com/inward/record.url?scp=33846564433&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846564433&partnerID=8YFLogxK

M3 - Articolo

C2 - 16385353

AN - SCOPUS:33846564433

VL - 57

SP - 30

EP - 33

JO - Reumatismo

JF - Reumatismo

SN - 0048-7449

IS - SUPPL. 4

ER -